{
    "nctId": "NCT02875951",
    "briefTitle": "Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer",
    "officialTitle": "Prospective, Non-interventional, Non-controlled Multicenter Observational Study to Evaluate Aspects of Pharmaceutical Care and the Treatment of Postmenopausal Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer Treated With Everolimus and Exemestane.",
    "overallStatus": "UNKNOWN",
    "conditions": "ER Positive, HER2 Negative Breast Cancer Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Medication adherence",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women, 18 years or older\n* Signed written informed consent\n* Patient can be contacted by phone and/or e-mail\n* HR+, HER2- advanced or metastatic breast cancer\n* Recurrence or progression following a non-steroidal aromatase inhibitor\n* Able to swallow and retain oral medication\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2\n\nExclusion Criteria:\n\n* Patients who are not able to understand Dutch or French\n* Symptomatic visceral metastatic disease\n* Patients who have taken an investigational drug within 28 days or 5 half-lives, whichever is shorter, prior to recruitment\n* Current use of a prohibited medication as described in the SPC\n* Any serious or unstable pre-existing medical conditions, psychiatric disorders, or other conditions that could interfere with the subject's safety, obtaining informed consent, or compliance with study procedure\n* Hypersensitivity to the active substances or to any of the excipients",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}